Taken together, these data strongly argue that the abolition of therapeutic benefit achieved with ICI alone by addition of virus to ICI therapy was due to a rapid induction/expansion of anti-viral effector CD8 cells at the expense of anti-tumor, PD-1 expressing terminal effector CD8+ T cells. The gene discussed is CD8A; the disease is neoplasm.